Tumour stem cells and drug resistance

Nature Reviews Cancer

Volumn 5, Issue 4, 2005, Pages 275-284

  Dean, Michael ^a   Fojo, Tito ^b   Bates, Susan ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BIRICODAR; CAMPTOTHECIN; CBT 1; CISPLATIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FLUOROURACIL; IMATINIB; IRINOTECAN; LANIQUIDAR; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; ONT 093; PACLITAXEL; QUINIDINE; SONIC HEDGEHOG PROTEIN; TARIQUIDAR; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ATAXIA; BLAST CELL CRISIS; BREAST CANCER; CELL TRANSFORMATION; CONTROLLED STUDY; DNA REPAIR; DRUG RESISTANCE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HYPOTENSION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TERATOCARCINOMA; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINEAGE; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; MICE; MODELS, ANIMAL; PLURIPOTENT STEM CELLS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR STEM CELLS;

EID: 16844368698     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1590     Document Type: Review

References (105)

1. Reya, T., Morrison, S. J., Clarke, M1 F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
2. Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43-47 (2004).
3. Morrison, S. J., Wandycz, A. M., Hemmati, H. D., Wright, D. E. & Weissman, I. L. Identification of a lineage of multipotent hematopoietic progenitors. Development 124, 1929-1939 (1997).
4. Dontu, G., Al-Hajj, M., Abdallah, W. M., Clarke, M. F. & Wicha, M. S. Stem cells in normal breast development and breast cancer. Cell Prolif. 36 (Suppl. 1), 59-72 (2003).
5. Kordon, E. C. & Smith, G. H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125, 1921-1930 (1998).
6. Price, J. E. & Tarin, D. Low incidence of tumourigenicity in agarose colonies from spontaneous murine mammary tumours. Differentiation 41, 202-207 (1989).
7. Gioanni, J. et al. In vitro clonogenicity in relation to kinetic and clinicopathological features of breast cancer. Bull. Cancer 75, 285-290 (1988).
8. Southam, C. M. & Brunschwig, A. Quantitative studies of autotransplantation of human cancer. Cancer 14, 971-978 (1960).
9. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994). Original report demonstrating the existence of stem cells in leukaemia.
10. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med. 3, 730-737 (1997).
11. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738-43 (2004).
12. Dick, J. E. Breast cancer stem cells revealed. Proc. Natl Acad. Sci. USA 100, 3547-3549 (2003).
13. Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
14. Andrews, P. W. From teratocarcinomas to embryonic stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 405-417 (2002).
15. Damjanov, I. Teratocarcinoma stem cells. Cancer Surv. 9, 303-319 (1990).
16. Sell, S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51, 1-28 (2004).
17. Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585-3589 (1975).
18. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003). Demonstrates a population of cells in breast cancers possessing markers in common with normal breast stem cells. Small numbers of these cancer stem cells could generate tumours in mice, whereas the non-cancer stem cells could not.
19. Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl Acad. Sci. USA 101, 4158-4163 (2004).
20. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
21. Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178-15183 (2003). Describes the isolation of tumour stem cells from paediatric brain cancers.
22. Singh, S. K., Clarke, I. D., Hide, T. & Dirks, P. B. Cancer stem cells in nervous system tumors. Oncogene 23, 7267-7273 (2004).
23. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
24. Richardson, G. D. et al. CD133. a novel marker for human prostate epithelial stem cells. J. Cell Sci. 117, 3539-3545 (2004).
25. Yu, S., Zhang, J. Z., Zhao, C. L., Zhang, H. Y. & Xu, Q. Isolation and characterization of the CD133* precursors from the ventricular zone of human fetal brain by magnetic affinity cell sorting. Biotechnol. Lett. 26, 1131-1136 (2004).
26. Wu, X. et al. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am. J. Physiol. Heart Circ. Physiol. 287, H480-H487 (2004).
27. Cozzio, A. et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-liked myeloid progenitors. Genes Dev. 17, 3029-3035 (2003).
28. Blanpain, C., Lowry, W. E., Geoghegan, A., Polak, L. & Fuchs, E. Self-Renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118, 635-648 (2004).
29. Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002).
30. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2, 48-58 (2002).
31. Kim, M. et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin. Cancer Res. 8, 22-28 (2002).
32. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. & Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58, 5337-5339 (1998).
33. Miyake, K. et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59, 8-13 (1999).
34. Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl Acad. Sci. USA 95, 15665-15670 (1998).
35. Dean, M., Rznetsky, A. & Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001).
36. Schinkel, A. H. et al. Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
37. Zhou, S., Zong, Y., Lu, T. & Sorrentino, B. P. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques 35, 1248-1252 (2003).
38. Zhou, S. et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl Acad. Sci. USA 99, 12339-12344 (2002).
39. Jonker, J. W. et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649-15654 (2002).
40. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797-1806 (1996).
41. Summer, R. et al. Side population cells and Bcrp1 expression in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L97-L104 (2003).
42. Alvi, A. J. et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5, R1-R8 (2003).
43. Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Med. 7, 1028-1034 (2001). Shows that ABCG2 is highly expressed in normal stem cells and is responsible for the low retention of fluorescent dyes used to identify the SP population.
44. Lassalle, B. et al. 'Side Population' cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells. Development 131, 479-487 (2004).
45. Asakura, A. & Rudnicki, M. A. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp. Hematol. 30, 1339-1345 (2002).
46. Martin, C. M. et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev. Biol. 265, 262-275 (2004).
47. Lechner, A., Leech, C. A., Abraham, E. J., Nolan, A. L. & Habener, J. F. Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem. Biophys. Res. Commun. 293, 670-674(2002).
48. Terunuma, A., Jackson, K. L., Kapoor, V., Telford, W. G. & Vogel, J. C. Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J. Invest. Dermatol. 121, 1095-1103 (2003).
49. Hirschmann-Jax, C. et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101, 14228-14233 (2004).
50. Kondo, T., Setoguchi, T. & Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA 101, 781-786 (2004). Shows that long-established cancer cell lines contain a small population of SP cells that behave as cancer stem cells. Like cancer stem cells isolated from brain tumours, these SP cells can give rise to the multiple differentiated cell types found in the cell line.
51. Mizoguchi, T. et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J. Natl Cancer Inst. 82, 1679-1683 (1990).
52. Nishiyama, K. et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 71, 3611-3619 (1993).
53. Bates, S. E. et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol. Cell. Biol. 9, 4337-4344 (1989).
54. Mickley, L. A. et al. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem. 264, 18031-18040 (1989).
55. Knutsen, T. et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosom. Cancer 23, 44-54 (1998).
56. Mickley, L. A., Spengler, B. A., Knutsen, T. A., Biedler, J. L. & Fojo, T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J. Clin. Invest. 99, 1947-1957 (1997).
57. Sato, N., Leopold, P. L. & Crystal, R. G. Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. J. Natl Cancer Inst. 93, 1858-1864 (2001).
58. Cotsarelis, G. & Millar, S. E. Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7, 293-301 (2001).
59. Houghton, P. J. et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64, 2333-2337 (2004).
60. Ozvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485-1495 (2004).
61. Burger, H. et al. Imatinib mesylate(STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942 (2004).
62. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
63. + acute lymphoblastic leukemia. Blood 102, 659-661 (2003).
64. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727-1733 (1979).
65. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensetive to STI571 in vitro. Blood 99, 319-325 (2002).
66. Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002).
67. Paterson, S. C., Smith, K. D., Holyoake, T. L. & Jorgensen, H. G. Is there a cloud in the silver lining for imatinib? Br. J. Cancer 88, 983-987 (2003).
68. La Rosee, P., Shen, L., Stoffregen, E. P., Deininger, M. & Druker, B. J. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). Hematol. J. 4, 413-419 (2003).
69. Agrawal, M. et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin. Cancer Res. 9, 650-656 (2003).
70. Bakker, M. et al. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. AntiCancer Res. 19, 2349-2353 (1999).
71. Bates, S. E. et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin. Cancer Res. 10, 4724-4733 (2004).
72. Peck, R. A. et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19, 3130-3141 (2001).
73. Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W. & Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60, 47-50 (2000).
74. Allen, J. D. et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1, 417-425 (2002).
75. Cisternino, S., Mercier, C., Bourasset, F., Roux, F. & Scherrmann, J. M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64, 3296-3301 (2004).
76. Weisenthal, L. M. & Lippman, M. E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 69, 615-632 (1985).
77. Secchi, G. C. Cancer chemotherapy. Ann. Ital. Med. Int. 5, 288-295 (1990).
78. Dean, M. Towards a unified model of tumor suppression: lessons learned from the human patched gene. Biochimica et Biophysica Acta 1332, M43-M52 (1997).
79. Nusslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
80. Hahn, H. et al. A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental anomalies, J. Biol. Chem. 271, 12125-12128 (1996).
81. Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996). Positional cloning of PTCH as the tumour-suppressor gene responsible for the nevoid basal-cell carcinoma syndrome. Established a role for the HH-PTCH pathway in cancer.
82. Johnson, R. L. et al. Human homolog of patched, a candidate gene for the Basal Cell Nevus Syndrome. Science 272, 1668-1671 (1996).
83. Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561 (2002).
84. Berman, D. M. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851 (2003).
85. Watkins, D. N. et al. Hedgehog signalling within airway epithelial progenitors and in small-cell tung cancer. Nature 422, 313-317 (2003).
86. Thayer, S. P. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856 (2003).
87. Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004).
88. Dalton, W. S. et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75, 815-820 (1995).
89. Belpomme, D. et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann. Oncol. 11, 1471-1476(2000).
90. Millward, M. J. et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer 67, 1031-1035 (1993).
91. Milroy, R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br. J. Cancer 68, 813-818 (1993).
92. Wishart, G. C. et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol. 12, 1771-1777 (1994).
93. Sonneveld, P. et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br. J. Haematol. 115, 895-902 (2001).
94. List, A. F. et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98, 3212-3220 (2001).
95. Greenberg, P. L. et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086 (2004).
96. Baer, M. R. et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100, 1224-1232 (2002).
97. Rago, R. P. et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemother. Pharmacol. 51, 297-305 (2003).
98. Seiden, M. V. et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. 86, 302-310 (2002).
99. Toppmeyer, D. et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 8, 670-678 (2002).
100. Bramwell, V. H. et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubidn in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin. Cancer Res. 8, 383-393 (2002).
101. Sparreboom, A. et al. Clinical pharmacokinetics of doxorubidn in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10, 719-728 (1999).
102. van Zuylen, L. et al. The orally administered P-glycoprotein inhibitor R101933 does not after the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6, 1365-1371 (2000).
103. Sandler, A. et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubidn in patients with advanced malignancy. Clin. Cancer Res. 10, 3265-3272 (2004).
104. Guns, E. S., Denyssevych, T., Dixon, R., Bally, M. B. & Mayer, L. Drug interaction studies between paclitaxel (Taxol) and OC144-093 - a new modulator of MDR in cancer chemotherapy. Eur. J. Drug Metab. Pharmacokinet. 27, 119-126 (2002).
105. Oldham, R. K., Barnett, D. & Ramos, Z. A phase II study of paclitaxel/CBT-1, an MDR modulator. Proc. Am. Soc. Clin. Oncol. 22, 148 (2003).